Anticancer research最新文献

{"title":"A Huge Hepatocellular Carcinoma With Major Arteriovenous Shunt Successfully Treated With Chemoembolization Plus Lenvatinib Therapy Followed by Radiotherapy.","authors":"Toshiro Masuda, Toru Beppu, Hideaki Miyamoto, Yasunori Nagayama, Yoshiyuki Fukugawa, Toshihiko Motohara, Yuki Adachi, Eri Oda, Ryuichi Karashima, Kazuaki Yoshizato, Takatoshi Ishiko","doi":"10.21873/anticanres.17558","DOIUrl":"10.21873/anticanres.17558","url":null,"abstract":"<p><strong>Background/aim: </strong>Large hepatocellular carcinoma (HCC) (defined as ≥10 cm) is associated with a poor prognosis in both resectable and unresectable patients. Liver resection and multidisciplinary treatment are recommended for solitary huge and multiple huge HCCs, respectively.</p><p><strong>Case report: </strong>The patient presented with a hypervascular HCC measuring over 10 cm in the right liver lobe and a suspected hypovascular tumor in the medial segment. He had nonB-nonC hepatitis with metabolic disease together with untreated 3-vessel coronary artery disease. Transarterial chemoembolization (TACE) and lenvatinib treatment were performed in parallel with coronary stent treatment. The treatment for HCC was effective, with the tumor's contrast enhancement almost completely disappearing and the protein induced by the absence of vitamin K or antagonist-II level decreasing from 91,616 mAU/ml to 152 mAU/ml. After portal vein embolization, the tumor became resectable; however, the patient did not consent to a major hepatectomy. Only contrast-enhanced ultrasonography showed viable tumor tissue near the hepatic hilar Glissonean capsule. These tumors were contraindicated for thermal ablation; therefore, intensity-modulated radiation therapy (30 Gy/10 fractions) was performed. Percutaneous microwave ablation was successfully applied to another growing HCC in the medial segment. Three years after the initial treatment, the patient remains well and free of disease.</p><p><strong>Conclusion: </strong>For patients who are contraindicative for immune checkpoint inhibitors or major liver resection, TACE plus lenvatinib followed by radiotherapy is safe and potentially an optimal treatment option.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1785-1792"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activation of <i>DCTN1-RET</i> Fusion Through Coiled-coil Domain as a Potential Target for RET Inhibitors.","authors":"Kohei Hayashi, Keiji Ishida, Masanori Kato, Shuichi Ohkubo, Yoshihiro Uto","doi":"10.21873/anticanres.17526","DOIUrl":"10.21873/anticanres.17526","url":null,"abstract":"<p><strong>Background/aim: </strong>The REarranged during Transfection (<i>RET</i>) proto-oncogene fusion is a typical cancer driver gene frequently observed in thyroid and lung cancers. This study characterized the novel dynactin subunit 1 <i>(DCTN1)-RET</i> fusion gene and evaluated the efficacy of RET inhibitors against this fusion.</p><p><strong>Materials and methods: </strong>Thyroid cancer tissue DNA samples were sequenced to identify fusion genes, and an expression vector was generated using extracted RNA. Cell lines stably expressing DCTN1-RET variants, including those lacking the coiled-coil (CC) domain, were established. The functionality of these variants and therapeutic efficacy of RET inhibitors were examined both <i>in vitro</i> and <i>in vivo</i>.</p><p><strong>Results: </strong>The <i>DCTN1-RET</i> fusion gene contains the CC domain from DCTN1 and the kinase domain from RET. Deletion of the CC domain abrogated dimer formation and reduced RET and extracellular signal-regulated kinase phosphorylation. Cells expressing <i>DCTN1-RET</i> exhibited enhanced proliferation and tumorigenesis <i>in vivo</i>. The RET inhibitor TAS0286 effectively suppressed <i>DCTN1-RET</i>-mediated RET autophosphorylation and tumor growth in a mouse subcutaneous tumor model.</p><p><strong>Conclusion: </strong><i>DCTN1-RET</i> is a novel oncogenic fusion gene in thyroid cancer that promotes tumorigenesis through CC domain-mediated dimerization. It represents a potential therapeutic target for RET-specific inhibitors.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1407-1417"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Treatment for Resectable Pancreatic Cancer.","authors":"Toru Aoyama, Kentaro Hara, Aya Saito, Haruhiko Cho","doi":"10.21873/anticanres.17519","DOIUrl":"10.21873/anticanres.17519","url":null,"abstract":"<p><p>Pancreatic cancer is the seventh leading cause of cancer-related death worldwide. Surgical resection, such as pancreatoduodenectomy or distal pancreatectomy, is the standard curative treatment for resectable pancreatic cancer. So far, several studies suggested that management of micro metastasis is one of the approaches to improve pancreatic cancer patients. The use of chemotherapy or chemo radiation therapy during perioperative periods is most promising adjuvant treatment. To introduce the adjuvant treatment during perioperative periods for pancreatic cancer, it is necessary to establish the optimal methods, regimen, and timing of adjuvant treatment. To date, many randomized trials have been conducted to examine the efficacy of adjuvant therapies. Since 2000, different evidence has emerged for postoperative adjuvant chemoradiation, postoperative adjuvant chemotherapy, and perioperative adjuvant chemotherapy for resectable pancreatic cancer. This review summarizes the background, current status, and future perspectives of adjuvant therapy for resectable pancreatic cancer.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1329-1341"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy Efficacy in Patients With Colorectal Cancer Experiencing Early Recurrence During or After Adjuvant Chemotherapy.","authors":"Dai Okemoto, Toshifumi Yamaguchi, Kanako Sugino, Nanako Matsuo, Makoto Sanomura, Shin Kameisihi, Toru Kadono, Hiroyuki Kodama, Hiroki Yukami, Elham Fakhrejahani, Hiroki Nishikawa","doi":"10.21873/anticanres.17550","DOIUrl":"10.21873/anticanres.17550","url":null,"abstract":"<p><strong>Background/aim: </strong>Colorectal cancer (CRC) is the third most diagnosed malignancy worldwide. The efficacy of first-line chemotherapy for metastatic CRC with early recurrence after adjuvant therapy remains unclear; therefore, this study investigated its impact.</p><p><strong>Patients and methods: </strong>A retrospective evaluation was conducted on patients with early recurrence after adjuvant chemotherapy from three institutions between 2016 and 2021. Early recurrence was defined as recurrence during or within 1 year of completing adjuvant chemotherapy. Progression-free and overall survival, as well as the overall response rate, were endpoints, with analysis stratified by a recurrence-free interval (RFI) of 6 months.</p><p><strong>Results: </strong>Data from 455 patients treated with adjuvant therapy were reviewed, identifying 32 eligible patients. Twenty-eight patients (88%) received oxaliplatin-containing regimens, and four (12%) received fluoropyrimidine monotherapy. For palliative chemotherapy, oxaliplatin-based, irinotecan-based, or other regimens were administered to 13 (41%), 13 (41%), and 6 (18%) patients, respectively. Median progression-free and overall survival were 10.4 and 43.0 months, respectively. The overall response rate was 34.4%, and the disease control rate was 75.0%. Patients with RFI <6 months had a lower response rate (26% <i>vs</i>. 56%), shorter progression-free survival (10.4 <i>vs</i>. 17.8 months), and shorter overall survival (31.3 <i>vs</i>. 43.0 months); however, these differences were not statistically significant. Multivariate analysis suggested worse overall survival for patients with RFI <6 months than for those with RFI ≥6 months (hazard ratio=1.78, 95% confidence interval=0.35-8.98; <i>p</i>=0.49).</p><p><strong>Conclusion: </strong>Patients with CRC and RFI <6 months after adjuvant chemotherapy showed a trend toward poorer outcomes than those with RFI ≥6 months, suggesting a need for more intensive treatment strategies.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1695-1705"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Outcomes for Patients With Advanced Renal Cell Carcinoma: Immuno-Oncology Era <i>Versus</i> Tyrosine Kinase Inhibitor Era in the IMDC Favorable-risk Group.","authors":"Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Koichi Nishimura, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi","doi":"10.21873/anticanres.17545","DOIUrl":"10.21873/anticanres.17545","url":null,"abstract":"<p><strong>Background/aim: </strong>Scarce data are available on the changes in outcomes related to advanced renal cell carcinoma (RCC), from the previous tyrosine kinase inhibitor (TKI) era to the current immuno-oncology (IO) era, among patients in the IMDC favorable-risk group.</p><p><strong>Patients and methods: </strong>Among 618 patients with previously untreated advanced RCC according to our database, 72 classified with an International Metastatic RCC Database Consortium (IMDC) favorable risk were selected. These patients were divided into two groups (IO and TKI eras) based on the treatments recognized as the standard of care at the time of their treatment. We compared the effectiveness and safety profiles according to the treatment era.</p><p><strong>Results: </strong>Out of 72 patients, 31 (43%) were treated in the IO era and 41 (57%) in the TKI era. No significant differences were found in patient backgrounds (<i>p</i>>0.05). Progression-free survival (median: 23.0 <i>vs</i>. 29.3 months, <i>p</i>=0.547) and overall survival (median: not reached <i>vs</i>. 114.7 months, <i>p</i>=0.785) showed no significant difference between the two eras. The objective response rate was higher in the IO era (84% <i>vs</i>. 41%, <i>p</i>=0.0003), and the treatment era was an independent predictor of an objective response (odds ratio=0.14, <i>p</i>=0.0006). The rates of treatment interruption (65% <i>vs</i>. 46%, <i>p</i>=0.155) and discontinuation (32% <i>vs</i>. 22%, <i>p</i>=0.420) did not significantly differ between eras.</p><p><strong>Conclusion: </strong>The implementation of IO therapies has enhanced tumor response rates among patients within the IMDC favorable-risk group, although extended follow-up is necessary to ascertain any survival benefits.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1643-1652"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall Incidence of Postoperative Pancreatic Fistula After Early Drain Removal in Distal Pancreatectomy.","authors":"Teruhisa Sakamoto, Jun Yoshida, Mikiya Kishino, Yuki Murakami, Kozo Miyatani, Yuji Shishido, Kyoichi Kihara, Manabu Yamamoto, Tomoyuki Matsunaga, Naruo Tokuyasu, Yoshiyuki Fujiwara","doi":"10.21873/anticanres.17553","DOIUrl":"10.21873/anticanres.17553","url":null,"abstract":"<p><strong>Background/aim: </strong>Detailed evaluation of the overall incidence of postoperative pancreatic fistula (POPF) after early drain removal (EDR) in distal pancreatectomy (DP) is lacking. This study aimed to assess postoperative complications, including the overall incidence of POPF, with EDR following DP.</p><p><strong>Patients and methods: </strong>Ninety-nine patients who underwent EDR after DP regardless of drain fluid amylase level between January 2017 and December 2024 were enrolled in this study. Data were retrospectively analyzed to evaluate complications, including the overall incidence of POPF.</p><p><strong>Results: </strong>The overall incidence of POPF after EDR was 31.3% (31/99 patients), of which the incidence of clinically relevant POPF requiring reinsertion of abdominal drains was 4.0% (4/99 patients). The incidence of Clavien-Dindo grade ≤ II POPF was high, at 27.3% (27/99 patients). There were no complications of Clavien-Dindo grade IV or V. Univariate analysis of pre- and intraoperative variables showed that injury to the pancreatic parenchyma near the pancreatic stump was the only risk factor for drain reinsertion after EDR.</p><p><strong>Conclusion: </strong>EDR, regardless of drain fluid amylase level, reduces the incidence of Clavien-Dindo grade ≥ IIIa POPF after DP. However, EDR does not necessarily contribute to a decrease in the overall incidence of POPF after DP.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1723-1730"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Programmed Cell Death 10 (<i>PDCD10</i>) Is a Candidate Tumor-associated Gene in Esophageal Squamous Cell Carcinoma.","authors":"Yoshiki Hiraki, Takaaki Masuda, Yushi Motomura, Taro Tobo, Hideyuki Saito, Kosuke Hirose, Takashi Ofuchi, Yasuo Tsuda, Hajime Otsu, Yusuke Yonemura, Satohiro Kai, Masakazu Hirakawa, Kousei Ishigami, Koshi Mimori","doi":"10.21873/anticanres.17527","DOIUrl":"10.21873/anticanres.17527","url":null,"abstract":"<p><strong>Background/aim: </strong>Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor survival rates. Effective molecular-targeted therapies are urgently needed. This study aimed to identify novel candidate tumor-associated genes in ESCC by analyzing chromosomal amplification regions.</p><p><strong>Materials and methods: </strong>DNA copy number variation (CNV) and mRNA expression data were obtained from The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE). Single-cell RNA sequencing data from Gene Expression Omnibus (GEO) were analyzed using Scanpy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded (FFPE) ESCC tissues. <i>PDCD10</i> was identified as a potential tumor-associated gene, and its association with clinicopathological factors and prognostic impact was evaluated using Kaplan-Meier survival and Cox regression analyses. Pathway analysis was performed to investigate the biological processes, and drug sensitivity profiling was conducted to identify compounds whose efficacy correlated with <i>PDCD10</i> expression in ESCC cell lines.</p><p><strong>Results: </strong><i>PDCD10</i>, a signaling protein involved in cell proliferation and vascular development, showed significant amplification and over-expression in ESCC cases. High <i>PDCD10</i> expression was associated with poor prognosis. Single-cell RNA sequencing confirmed its tumor-specific expression. GSEA revealed enrichment of mTORC1 signaling, E2F, and Myc target pathways in high <i>PDCD10</i>-expressing tumors. Drug sensitivity analysis identified Azelaic acid and Rebamipide as compounds whose efficacy correlated with <i>PDCD10</i> expression in ESCC cell lines.</p><p><strong>Conclusion: </strong><i>PDCD10</i> could be a novel tumor-associated gene associated with tumor progression and poor prognosis in ESCC. Azelaic acid and Rebamipide are candidate therapeutic agents targeting <i>PDCD10</i>.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1419-1433"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Body Mass Index on Sentinel Lymph Node Identification in Endometrial Cancer.","authors":"Roxani Dampali, Konstantinos Nikolettos, Iason Psilopatis, Evangelia-Georgia Kostaki, Andreas John Papadopoulos, Stephen Attard-Montalto, Omer Devaja","doi":"10.21873/anticanres.17538","DOIUrl":"10.21873/anticanres.17538","url":null,"abstract":"<p><strong>Background/aim: </strong>Endometrial cancer, a prevalent gynecologic malignancy, is often associated with obesity. Sentinel lymph node (SLN) mapping, a minimally invasive staging method, reduces the need for extensive lymphadenectomy, thereby minimizing surgical morbidity. However, the influence of body mass index (BMI) on SLN mapping outcomes is not fully understood. This study evaluated the relationship between BMI and SLN mapping success using data from a large and diverse patient cohort.</p><p><strong>Patients and methods: </strong>A retrospective study of 112 patients diagnosed with endometrial carcinoma was conducted. Patients were categorized into non-obesity (BMI <30 kg/m²) and obesity (≥30 kg/m²) groups. All underwent laparoscopic hysterectomy with SLN mapping using indocyanine green (ICG) dye. Statistical analysis was performed using univariable and multivariable logistic regression models.</p><p><strong>Results: </strong>LN detection rates were 77.7% overall, with bilateral mapping achieved in 54.5% of patients. Mapping success was higher in the non-obesity group (59.7%) compared to the obesity group (49.1%; <i>p</i>=0.099). Mapping failure rates were notably higher in obese patients (30.9%) <i>versus</i> non-obese patients (14.0%) (<i>p</i>=0.099). Multivariable logistic regression analysis identified advanced cancer stage as a significant predictor of SLN biopsy positivity (adjusted odds ratio=30.2, <i>p</i>=0.002).</p><p><strong>Conclusion: </strong>Obesity negatively impacts the technical success of SLN mapping in endometrial cancer, with lower bilateral detection rates and higher mapping failures observed in obese patients. These findings underscore the need for surgical strategies tailored to obese patients, such as optimizing tracer injection techniques, utilizing advanced imaging technologies, and incorporating preoperative planning to account for anatomical challenges. Addressing these factors may enhance SLN detection and improve staging accuracy in this high-risk population.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1575-1581"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Postoperative Outcomes of Laparoscopic <i>Versus</i> Open Gastrectomy in Older Patients With Gastric Cancer.","authors":"Tomohiro Takahashi, Tomoyuki Matsunaga, Hiroaki Saito, Tomohiro Osaki, Sadamu Takahashi, Akemi Iwamoto, Kenji Fukuda, Kenjiro Taniguchi, Hirohiko Kuroda, Tsutomu Takeuchi, Kenji Sugamura, Kenichi Sumi, Kuniyuki Katano, Shota Shimizu, Yuji Shishido, Kozo Miyatani, Teruhisa Sakamoto, Yoshiyuki Fujiwara","doi":"10.21873/anticanres.17548","DOIUrl":"10.21873/anticanres.17548","url":null,"abstract":"<p><strong>Background/aim: </strong>Several studies have investigated the safety of laparoscopic gastrectomy (LG) for gastric cancer (GC). However, many of these studies excluded older patients, and few multicenter studies have compared LG and open gastrectomy (OG) in older patients with GC. We compared the postoperative short- and long-term outcomes of LG and OG in >75 years old patients with GC in a multicenter study.</p><p><strong>Patients and methods: </strong>The study included 926 patients aged >75 years who underwent gastrectomy from January 2003 to December 2017 at 12 regional hospitals. After propensity score-matching (PSM), the two surgical groups' short- and long-term outcomes were analyzed. PSM was applied for variables such as sex, depth of tumor invasion, lymph node metastasis, histologic type, pathological stage, gastrectomy, and lymph node dissection.</p><p><strong>Results: </strong>After 1:1 matching, 258 cases in each group were analyzed. The LG group showed significantly longer surgery times and reduced blood loss (<i>p</i><0.001). There were no significant differences in the incidence of postoperative complications graded Clavien-Dindo ≥ II between the groups (23.6% <i>vs</i>. 19.4%, <i>p</i>=0.239). However, the LG group had lower and higher incidences of pneumonia (1.9% <i>vs</i>. 5.4%, <i>p</i>=0.035) and pancreatic fistula (PF; 4.7% <i>vs</i>. 0.04%, <i>p</i>=0.003), respectively. The two groups had no significant overall and disease-specific survival differences across all stages.</p><p><strong>Conclusion: </strong>In patients aged >75 years with GC, LG can be a viable approach with careful clinical management for the risk of PF, without compromising long-term survival.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1667-1679"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splenic Angiosarcoma and Numerous Liver Metastases Presenting the Kasabach-Merritt Phenomenon.","authors":"Toshiro Masuda, Toru Beppu, Yasunori Nagayama, Hideaki Miyamoto, Yoshihiro Komohara, Eri Oda, Ryuichi Karashima, Takashi Nakagaki, Yuki Adachi, Takatoshi Ishiko","doi":"10.21873/anticanres.17557","DOIUrl":"10.21873/anticanres.17557","url":null,"abstract":"<p><strong>Background/aim: </strong>Splenic angiosarcoma is a rare and serious malignancy. We investigated the diagnosis and the suitable treatment strategy for metastatic splenic angiosarcoma with the Kasabach-Merritt phenomenon.</p><p><strong>Case report: </strong>A 76-year-old man was referred because of abdominal discomfort together with anemia, thrombocytopenia, and disseminated intravascular coagulopathy. Contrast-enhanced computed tomography revealed some huge, low-attenuation large splenic tumors and numerous liver tumors. Magnetic resonance imaging showed tumors with low and heterogeneous high signal intensity on T1-weighted and T2-weighted images, respectively. Several splenic tumors contained peripheral hypointense areas on T2WI that demonstrated a signal drop in in-phase compared to opposed-phase chemical-shift T1WI. A percutaneous needle biopsy of liver tumors with needle-tract radiofrequency ablation was performed without bleeding. The patient was pathologically diagnosed as splenic angiosarcoma by several immunohistochemical analyses. We started anticoagulant-fibrinolytic therapy with nafamostat mesylate; however, partial ischemia of the jejunum happened twice, and partial resections and the creation of an ileostomy were performed. The patient has been relatively stable for 3 months with paclitaxel monotherapy followed by oral pazopanib. Kasabach-Merritt phenomenon has been stable during good control of splenic angiosarcoma.</p><p><strong>Conclusion: </strong>Metastatic splenic angiosarcoma with the Kasabach-Merritt phenomenon might be controlled by accurate diagnosis, precise surgical intervention for digestive organ ischemia, and effective chemotherapy. The Kasabach-Merritt phenomenon is an effective indicator of chemotherapy response. Furthermore, the development and clinical application of new chemotherapies are needed.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1777-1784"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}